In 2013, Merck committed to reducing the cost of its implants by approximately 50 percent for six years, through 2018. In 2015, Merck pledged to extend access pricing for its single-rod, long-acting, reversible contraceptive implants—in FP2020 focus countries for an additional five years through 2023. At the time of their revitalized commitment, the number of implants provided in targeted countries had doubled, bringing greater choice to millions of women in some of the world’s poorest regions. Merck continues to work with the Bill & Melinda Gates Foundation and other FP2020 partners in implementing the IMPLANON® Access Program.
Merck Announces Extension of Access Pricing for Contraceptive Implants
As part of our ongoing commitment to improving access to health and in support of the UN Secretary-General’s Global Strategy for Women’s, Children’s and Adolescents’ Health, the Every Woman, Every Child movement, today, Merck is proud to announce the extension of its access pricing for IMPLANON NXT® to these same targeted countries through 2023.
Merck (MSD) FP2020 Commitment
Merck, known as MSD outside the United States and Canada, commits to extending access pricing for IMPLANON® and IMPLANON NXT®—its single-rod, long-acting, reversible contraceptive implants—in FP2020 focus countries for an additional five years through 2023. This builds on Merck’s original announcement in May 2013 to reduce the cost of its implants by approximately 50 percent for six years, through 2018.
Merck (MSD) Commitment Self-reporting Questionnaire 2016
In July 2016, Merck shared the following update on progress in achieving its Family Planning 2020 commitment during the 2015-2016 time period.
Implant Access Program: Expanding Family Planning Options for Women
A group of public and private organizations collaborated to make Bayer’s Jadelle® and MSD’s Implanon NXT® available to women in the world’s poorest countries at price reductions of approximately 50% through 2018 (price reductions subsequently extended to 2023).